FibroBiologics, Inc. Common Stock FBLG · Stock Open FibroBiologics, Inc. Common Stock in new tab

0.6271 USD

Add to portfolio

EPS

-6.64

P/B

1.00

ROE

-754.75

Beta

1.17

Target Price

13.50 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for FibroBiologics, Inc. Common Stock (FBLG)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

FibroBiologics, Inc. Common Stock Analysis (FBLG)

Official Website Stock

Is FibroBiologics, Inc. Common Stock a good investment? FibroBiologics, Inc. Common Stock (FBLG) is currently trading at 0.6271 USD. Market analysts have a consensus price target of 13.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: FibroBiologics, Inc. Common Stock is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -4.49.

Investor FAQ

Does FibroBiologics, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is FibroBiologics, Inc. Common Stock?

FibroBiologics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -6.64.

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Exchange Ticker

FBLG

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
March 30, 2026	0.050000

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.